Merck KGaA said the European Commission or EC has approved extension of the indication of Rebif, a treatment for relapsing forms of multiple sclerosis or MS. This EC approval, based on REFLEX study results, is for the use of Rebif 44 micrograms three times weekly in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS....Read More http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1901